Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acasti Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Acasti Pharma şirketinin toplam hissedar öz sermayesi $59.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $69.7M ve $10.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$19.41m
Eşitlik	US$59.36m
Toplam yükümlülükler	US$10.35m
Toplam varlıklar	US$69.72m

Son finansal sağlık güncellemeleri

Recent updates

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Sep 02

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Apr 20

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Nov 14

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

May 10

Acasti Pharma GAAP EPS of -$0.10

Aug 11

Acasti inks deal for Grace Therapeutics, shares surge

May 07

Acasti Pharma issues clarification on trading activity

Dec 23

Acasti Pharma EPS in-line

Nov 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ACST 'nin kısa vadeli varlıkları ( $20.4M ) kısa vadeli yükümlülüklerini ( $2.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: ACST şirketinin kısa vadeli varlıkları ( $20.4M ) uzun vadeli yükümlülüklerini ( $7.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ACST borçsuzdur.

Borcun Azaltılması: ACST şirketinin 5 yıl önce borç/öz sermaye oranı 43.5% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ACST şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ACST serbest nakit akışı her yıl % { 9.2 1.1 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

Acasti Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Recent updates

Acasti Pharma Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc., Annual General Meeting, Sep 30, 2024

Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial

New major risk - Revenue and earnings growth

Acasti Pharma Inc. to Attend BIO International Convention 2024

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

New major risk - Revenue and earnings growth

Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc. Announces Board Changes

Independent Chairman recently bought US$1.2m worth of stock

Acasti Pharma Inc. announced that it has received $7.499388 million in funding from S S Pharma Llc, Shore Pharma Llc

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol

Acasti Pharma Inc. Announces Scientific Advisory Board Appointments

Forecast to breakeven in 2024

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Forecast to breakeven in 2024

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q2, 2023 Results on Nov 14, 2022

Acasti Pharma Inc. Announces Board Changes

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma Inc. to Report Q1, 2023 Results on Aug 11, 2022

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2022

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Less than half of directors are independent

Less than half of directors are independent

Acasti Pharma Inc. Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, its Lead Drug Candidate for Treatment of Subarachnoid Hemorrhage

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Insufficient new directors

Acasti Pharma Inc. (TSXV:ACST) completed the acquisition of Grace Therapeutics, Inc.

Forecast breakeven pushed back to 2024

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (TSXV:ACST) entered into a definitive agreement to acquire Grace Therapeutics, Inc. for $71.4 million.

Acasti inks deal for Grace Therapeutics, shares surge

Earnings miss expectations

New 90-day high: US$0.90

New 90-day high: US$0.57

New 90-day high: US$0.43

Acasti Pharma issues clarification on trading activity

New 90-day high: US$0.29

Acasti Pharma Inc. Announces Resignation of Brian Groch as Chief Commercial Officer, Effective December 31, 2020

Acasti Pharma EPS in-line

Acasti Pharma Inc. Announces Executive Changes

New 90-day low - US$0.24

Acasti Pharma Inc. Auditor Raises 'Going Concern' Doubt

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin